Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation.
Burkitt lymphoma
Donor
Hematopoietic stem cell transplantation
Next generation sequencing
Pseudo-autologous transplantation
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
28
06
2022
accepted:
13
09
2022
revised:
13
09
2022
pubmed:
23
9
2022
medline:
3
2
2023
entrez:
22
9
2022
Statut:
ppublish
Résumé
Donor-derived hematological malignancies have been recognized as rare but serious late complications in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Most cases in the literature were diagnosed as myelodysplastic syndrome or acute leukemia, with very few malignant lymphoma reported. We herein present another case of donor-derived Burkitt lymphoma that occurred 9 years after allo-HSCT under continued administration of immunosuppressants for chronic graft-versus-host disease (GVHD). The patient achieved a partial response after rituximab-combined intensive chemotherapy. To reduce the risk of relapse and to avoid organ toxicities due to repeated chemotherapies, we performed upfront high-dose chemotherapy followed by stem cell rescue using donor-derived CD34
Identifiants
pubmed: 36136227
doi: 10.1007/s12185-022-03458-x
pii: 10.1007/s12185-022-03458-x
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-292Informations de copyright
© 2022. Japanese Society of Hematology.
Références
Fialkow PJ, Bryant JI, Thomas ED, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1971;1(7693):251–5.
doi: 10.1016/S0140-6736(71)90998-6
Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, et al. Donor cell-derived hematological malignancy: a survey by the Japan society for hematopoietic cell transplantation. Leukemia. 2016;30(8):1742–5.
doi: 10.1038/leu.2016.23
Baker KS, Defor TE, Burns LJ, Ramsay NKC, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21(7):1352–8.
doi: 10.1200/JCO.2003.05.108
Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transpl. 2011;17(6):771–89.
doi: 10.1016/j.bbmt.2010.10.010
Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.
doi: 10.1200/JCO.2010.28.1618
Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–6.
doi: 10.1200/JCO.2013.53.9593
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–90.
doi: 10.1056/NEJMoa1301077
Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, et al. Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 2016;34(33):4015–22.
doi: 10.1200/JCO.2016.67.2980
Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transpl. 2002;29(8):709–10.
doi: 10.1038/sj.bmt.1703550
Jaing TH, Tseng CK, Mun-Ching Wong A, Lo WC, Wu CT, et al. Rescue by hematopoietic progenitor cells derived from engrafted cord blood unit in a child with brain tumor after transplantation for T-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012;34(7):573–5.
doi: 10.1097/MPH.0b013e318241fcf1
Tamaki M, Wada H, Gomyo A, Hayakawa J, Akahoshi Y, Harada N, et al. Pseudo-autologous stem cell transplantation for donor-derived mantle cell lymphoma 12 years after allogeneic transplantation. Int J Hematol. 2018;107:117–21.
doi: 10.1007/s12185-017-2296-z
Palfreyman E, Song K, Nantel S. Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic SCT. Bone Marrow Transpl. 2013;48(8):1138.
doi: 10.1038/bmt.2013.12
Hatsuse M, Taniguchi-Yoshihara K, Yagyu S, Fuchida S, Okano A, Murakami S, et al. Successful treatment with pseudo—autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogeneic bone marrow transplantation. Rinsho Ketsueki. 2015;56(4):428–31.
Miyamoto T, Nagafuji K, Fujisaki T, Uchida N, Matsue K, Henzan H, et al. Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. Int J Hematol. 2018;107(4):468–77.
doi: 10.1007/s12185-017-2389-8
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institute of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21(3):389–401.
doi: 10.1016/j.bbmt.2014.12.001
Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K, Hidaka M, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol. 2009;90:253–60.
doi: 10.1007/s12185-009-0370-x
Williams KM, Chen GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:710–6.
doi: 10.1016/j.bbmt.2015.10.009
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321–5.
doi: 10.1038/ng.2468
Panea RI, Love CL, Shingleton JR, Reddy A, Bailey JA, Moormann AM, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134:1598–607.
doi: 10.1182/blood.2019001880
Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–25.
doi: 10.1056/NEJMoa1308392
Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, et al. Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki. 1994;35:635–41.
Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95:1513–9.
doi: 10.1007/s00277-016-2740-9
Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation: a survey of the European group for blood and marrow transplantation (EBMT). Haematologica. 2005;90(7):969–75.
Dietz AC, DeFor TE, Brunstein CG, Wagner JE Jr. Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response. Br J Haematol. 2014;166(2):209–12.
doi: 10.1111/bjh.12847
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–8.
doi: 10.1038/nature12213
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.
doi: 10.1186/s13073-017-0424-2
Tsukamoto H, Nagafuji K, Horiuchi T, Miyamoto T, Aoki K, Takase K, et al. A phase I–II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis. 2006;65(4):508–14.
doi: 10.1136/ard.2005.037879
Ayano M, Tsukamoto H, Mitoma H, Kimoto Y, Akahoshi M, Arinobu Y, et al. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan. Arthr Res Ther. 2019;21:30.
doi: 10.1186/s13075-019-1823-0
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.
doi: 10.1016/j.bbmt.2008.03.005